(original) (raw)

TY - JOUR AU - Sałaga, M. AU - Lewandowska, U. AU - Sosnowska, D. AU - Zakrzewski, P. K. AU - Cygankiewicz, A. I. AU - Piechota-Polańczyk, A. AU - Sobczak, M. AU - Mosinska, P. AU - Chen, Chunqiu AU - Krajewska, W. M. AU - Fichna, J. PY - 2014 DA - 2014/11/01 TI - Polyphenol extract from evening primrose pomace alleviates experimental colitis after intracolonic and oral administration in mice JO - Naunyn-Schmiedeberg's Archives of Pharmacology SP - 1069 EP - 1078 VL - 387 IS - 11 AB - Oenothera paradoxa (EP) preparations are commonly used in folk medicine to treat skin diseases, neuralgia, and gastrointestinal (GI) disorders. Several reports suggested that EP preparations exhibit potent anti-inflammatory and antioxidant activities both in vitro and in vivo. Here, we aimed to characterize the action of EP pomace polyphenol extract in mouse model of colitis. We analyzed the composition of EP pomace polyphenol extract using reversed phase HPLC system and ultra-performance liquid chromatography (UPLC) system coupled with a quadrupole-time of flight (Q-TOF) MS instrument. Then, we used a well-established animal model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis to determine the anti-inflammatory action of EP pomace polyphenol extract. We also investigated the effect of the EP pomace polyphenol extract on pro-inflammatory (IL-1β and TNF-α) cytokine mRNA levels and hydrogen peroxide concentration in the inflamed colon. Administration of EP pomace polyphenol extract significantly improved macroscopic and microscopic damage scores, as well as myeloperoxidase (MPO) activity in TNBS-treated mice. The anti-inflammatory effect of the extract was observed after intracolonic and oral administration and was dose-dependent. Significant reduction of tissue hydrogen peroxide level after treatment with EP pomace polyphenol extract suggests that its therapeutic effect is a result of free radical scavenging. This novel finding indicates that the application of the EP pomace polyphenol extract in patients with inflammatory bowel diseases (IBDs) may become an attractive supplementary treatment for conventional anti-inflammatory therapy. SN - 1432-1912 UR - https://doi.org/10.1007/s00210-014-1025-x DO - 10.1007/s00210-014-1025-x ID - Sałaga2014 ER -